AbbVie

Open: 138.72 Close: 137.56 Change: -1.16

You don't have time to read all about AbbVie Company Inc. An AI summarizes all the information for you.

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, stock, ABBV, Abbvie, year, announce, disease, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie stock (ABBV) is a better pick than its industry peer, Eli Lilly stock (LLY) LLY stock trades at a higher valuation of 14.6x trailing revenues, compared to just 4.2x for Abbvie ABBv. Eli Lillys strong pipeline potential also seems to be priced in by investors. The company has been one of the busiest of its industry stock selection notification HUD 102 EFFtain troubles comprised fumble OstÉ Import

Today's News

AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Eli Lilly stock (LLY) LLY stock trades at a higher valuation of 14.6x trailing revenues, compared to just 4.2x for Abbvie ABBv. LLYs strong pipeline potential also seems to be priced in by investors. AbbVie Inc. (ABBV) stock price, quote & news - stock analysis. In 2022, Abbvies revenue was $58.05 billion, an increase of 3.30% compared to the previous years $56.20 billion. Price Target $166.81 (21.26% upside) Analyst Consensus: Buy stock forecasts. AbbVie will announce its first-quarter 2023 financial results on Thursday, April 27, 2023, before the market opens. RINVOQ is a selective JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. FDA approves EPKINLY as the First and Only Bispecific Antibody to Treat Adult Patients with R/R DLBCL AbbVie announced U.S. GenmabVie is transforming standards of care for blood cancers. AbbVie (ABBV) pays a dividend yield of 4.1%, which is more than double the S&P 500 average of 1.7%. The company has been one of the stocks most watched by Zacks users lately. FDA approves AbbVies (ABBV) Rinvoq for Crohns Disease. FDA approves the approval of the drug for the treatment of adults with moderately to severely active Crohns disease. AbbVie stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences. Analysts estimate an earnings decrease this quarter of $0.46 per share. AbbVie will announce its first-quarter 2023 financial results on Thursday, April 27, 2023, before the market opens. The company will host a live webcast of the earnings conference call. Abbvie stock quotes can also be displayed as NYSE : ABBV. If you had invested in AbbVie stock at $35.12 in 2013, your return over the last 10 years would have been 291.69%. AbbVie has been recognized as one of the most community-minded companies in the U.S. Learn more about work in immune-mediated disease: https://bit.ly/3otb1PN. AbbVie New York, NY - 1025 jobs New York. Jobs May, 2023 (Hiring Now!) - Zippia. Historically, weve worked collaboratively with AbbVies Patient Assistance Program, and remain hopeful that Abbvie will cease this misguided crusade and go back to working with us to achieve the best outcomes for the patients we serve.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, stock, ABBV, Abbvie, year, announce, disease, and the most common words in the summary are: abbvie, stock, abbv, job, market, report, new, . One of the sentences in the summary was: Eli Lillys strong pipeline potential also seems to be priced in by investors. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #abbv #job #market #report #new.